Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Trial of ZVS101e in Bietti's Crystalline Dystrophy
NCT04722107Phase 1Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2021
- Primary completion
- Jan 2024
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZVS101e in Bietti crystalline dystrophy (BCD), sponsored by Beijing Tongren Hospital. Primary endpoints: Incidence of adverse events at 24 months, Incidence of serious adverse events at 24 months and 1 more. Status: unknown.
02
Drugs
ZVS101e
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT04722107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722107.